Sun Pharma hit with another fire at an Indian plant

By Staff Reporter

- Last updated on GMT


Related tags Pharmaceutical drug Pharmacology Sun pharma

Sun Pharma says there was no direct loss of production at its Gujarat active pharmaceutical ingredient (API) facility following a fire last week.

According to Indian drugmaker Sun Pharma, a fire broke out within the solvent storage area at its API facility in Ankleshwar, Gujarat during the early hours of February 4.

The news was broken by Indian media (footage taken from the scene by news outlet Connect Gujarat TV can be seen below) and confirmed several days later by Sun Pharma in a filing with the Bombay Stock Exchange.

“The fire was put off by the site firefighting team with support from the DMPC fire tenders. There were no injuries during this incident and the situation is under control. There was no direct loss of production because of this incident,”​ the firm said.

“A detailed investigation is under progress.”

The firm added as this is not a material event under Regulation 30 of the Listing Regulations it has no bearing on the company’s performance.

No further details were divulged when in-Pharmatechnologist contacted the firm.

The facility makes a number of APIs and pharma intermediates and has ISO 9002 and WHO GMP accreditation.

This is the second fire to hit Sun Pharma’s manufacturing network within 14 months. A fire broke out at the company’s Ahmednagar factory on December 28, 2016​ during excavation work, killing two employees.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...